Genitourinary Cancers Symposium (ASCO GU) | Conference

One in Five Cancer Trials End Too Early, but GU Studies Not More Likely

January 28th 2014

The premature termination of clinical trials in the oncology setting is a problem that continues to vex researchers.

Dr. Robert Motzer Reviews the Phase III COMPARZ Study

March 5th 2013

Robert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the COMPARZ trial that compared pazopanib to sunitinib as a first-line therapy for patients with metastatic renal cell carcinoma.

Dr. Antonarakis Describes the TAXYNERGY Trial in mCRPC

February 25th 2013

Emmanuel Antonarakis, MBBCh, from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the TAXYNERGY trial that is exploring molecular markers of response in men with mCRPC following an early switch in taxane-based treatment.

Dr. Deepak Kapoor on Integrated Urology Practices

February 21st 2013

Deepak A. Kapoor, MD, president of the Large Urology Group Practice Association, discusses the greater exposure to high-quality healthcare that is provided by the integration of ancillary services into community urology practices.

Dr. Galsky on a Post-Treatment Nomogram in Urothelial Cancer

February 20th 2013

Matthew D. Galsky, MD, from the Mount Sinai Medical Center Tisch Cancer Institute, discusses the development of a post-treatment prognostic model for patients with metastatic urothelial cancer.

Dr. Weiss on PPAR-Alpha as a Target in Kidney Cancer

February 19th 2013

Robert H. Weiss, MD, from the UC Davis Comprehensive Cancer Center, discusses peroxisome PPAR-alpha as a possible new treatment target for patients with renal cell carcinoma.

Dr. Huang Compares Surveillance and Treatment in Kidney Cancer

February 18th 2013

William C. Huang, MD, from the New York University Langone Medical Center, discusses findings from a SEER database analysis that compared surveillance to surgical resection in elderly patients with small renal masses.

The 2013 Genitourinary Cancers Symposium

February 18th 2013

The 2013 Genitourinary Cancers Symposium was held at the Rosen Shingle Creek, Orlando, Florida, from February 14-16.

Dr. Cooperberg on Earlier Treatment With Sipuleucel-T

February 16th 2013

Matthew Cooperberg, MD, MPH, from the University of California, San Francisco, discusses the earlier administration of treatment with sipuleucel-T for men with prostate cancer.

PFS Not Significantly Better With First-Line Axitinib Versus Sorafenib in mRCC

February 16th 2013

Axitinib did not demonstrate superiority over sorafenib as first-line therapy for patients with metastatic renal cell carcinoma, on the endpoint of progression-free survival.

No Survival Advantage for Tivozanib Over Sorafenib in TIVO-1 Study

February 16th 2013

Tivozanib did not show a significant difference in overall survival when compared with sorafenib in patients with renal cell carcinoma who received up to one prior line of therapy excluding targeted agents.

Dr. Vogelzang Discusses Radium-223 in Prostate Cancer

February 16th 2013

Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada, discusses an updated analysis of the phase III ALSYMPCA trial that examined radium-223 dichloride in patients who have CRPC with bone metastases.

Tandems of Targeted Therapy No Better Than Bevacizumab Alone in Advanced Renal Cell Carcinoma

February 16th 2013

Combination targeted therapy did not significantly extend progression-free survival compared with single-agent bevacizumab in patients with advanced renal cell carcinoma.

Dr. Scher on Corticosteroids and Enzalutamide in mCRPC

February 15th 2013

Howard I. Scher, MD, from Memorial Sloan-Kettering Cancer Center, discusses the impact of corticosteroids on outcomes for men with metastatic castration-resistant prostate cancer receiving treatment with enzalutamide.

Dr. Motzer Analyzes Overall Survival in the TIVO-1 Study

February 15th 2013

Robert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the overall survival results from the phase III TIVO-1 study that compared tivozanib to sorafenib in patients with renal cell carcinoma.

Dasatinib Combination Fails to Improve Outcomes in mCRPC

February 15th 2013

The addition of dasatinib to standard therapy with docetaxel failed to improve survival and most other clinical endpoints in men with metastatic castration-resistant prostate cancer in the phase III READY trial.

Abiraterone Continues to Show Survival Benefit in Updated Interim Analysis

February 15th 2013

An updated interim analysis of the COU-AA-302 trial upholds the benefits of abiraterone acetate in mildly symptomatic or asymptomatic patients with progressive mCRPC untreated with prior chemotherapy.

Concomitant Corticosteroid Use Dilutes Benefit of Enzalutamide in mCPRC

February 15th 2013

Use of corticosteroids had a negative impact on outcomes with enzalutamide treatment as well as placebo treatment in men with metastatic castrate resistant prostate cancer.

Dr. William Oh Discusses the COU-AA-302 Trial

February 15th 2013

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the third interim analysis of the COU-AA-302 trial that examined abiraterone acetate before chemotherapy in mCRPC.

Dr. Nabid on a Shorter Duration of ADT in Prostate Cancer

February 14th 2013

Abdenour Nabid, MD, from the Centre Hospitalier de Universitaire de Sherbrooke in Sherbrooke, Canada, discusses results of a phase III randomized study that compared 18 months of ADT to 36 in men with high-risk, localized prostate cancer.